Alsace BioValley in €4.4M project to develop stem cells for use in drug discovery

14 Oct 2009 | News
The Alsace BioValley cluster has launched SHIP-In, a project to develop induced pluripotent stem cells for use in drug discovery.


Embryonic stem cell lines are becoming increasingly important tools in drug discovery, but their use remains controversial. The SHIP-In project has been set up to optimise new techniques for inducing adult cells to revert to stem cells.

“SHIP-In presents a unique opportunity to participate in the development of scientific advances that have been unanimously hailed at a world level,” said Nicolas Carboni, the Director of the Alsace BioValley cluster. “Alsace BioValley is proud to have supported and endorsed a project of this importance, which can only enhance the competitiveness of French researchers on the world stage.”

SHIP-In is one of three Alsatian R&D projects to have been selected by the French government, following a seventh call for projects issued in September 2008. Three organisations based in Alsace: the biotech company Polyplus Transfection, the Institute of Genetics and Molecular and Cellular Biology, a biomedical research centre, and the Institut Charles Sadron, are involved in the project.

Never miss an update from Science|Business:   Newsletter sign-up